Literature DB >> 16648559

Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence.

Tao Yan1, Yuji Seo, Jane E Schupp, Xuehuo Zeng, Anand B Desai, Timothy J Kinsella.   

Abstract

We previously reported that methoxyamine (an inhibitor of base excision repair) potentiates iododeoxyuridine (IUdR)-induced radiosensitization in human tumor cells. In this study, we investigated the potential mechanisms of this enhanced cell death. Human colorectal carcinoma RKO cells were exposed to IUdR (3 micromol/L) and/or methoxyamine (3 mmol/L) for 48 hours before ionizing radiation (5 Gy). We found that IUdR/methoxyamine altered cell cycle kinetics and led to an increased G1 population but a decreased S population before ionizing radiation. Immediately following ionizing radiation (up to 6 hours), IUdR/methoxyamine-pretreated cells showed a stringent G1-S checkpoint but an insufficient G2-M checkpoint, whereas a prolonged G1 arrest, containing 2CG1 and 4CG1 cells, was found at later times up to 72 hours. Levels of cell cycle-specific markers [p21, p27, cyclin A, cyclin B1, and pcdc2(Y15)] and DNA damage signaling proteins [gammaH2AX, pChk1(S317), and pChk2(T68)] supported these altered cell cycle kinetics. Interestingly, we found that IUdR/methoxyamine pretreatment reduced ionizing radiation-induced apoptosis. Additionally, the extent of cell death through necrosis or autophagy seemed similar in all (IUdR +/- methoxyamine + ionizing radiation) treatment groups. However, a larger population of senescence-activated beta-galactosidase-positive cells was seen in IUdR/methoxyamine/ionizing radiation-treated cells, which was correlated with the increased activation of the senescence factors p53 and pRb. These data indicate that IUdR/methoxyamine pretreatment enhanced the effects of ionizing radiation by causing a prolonged G1 cell cycle arrest and by promoting stress-induced premature senescence. Thus, senescence, a novel ionizing radiation-induced tumor suppression pathway, may be effectively targeted by IUdR/methoxyamine pretreatment, resulting in an improved therapeutic gain for ionizing radiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648559     DOI: 10.1158/1535-7163.MCT-05-0364

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  4 in total

1.  5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts.

Authors:  Timothy J Kinsella; Michael T Kinsella; Yuji Seo; Gregory Berk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

2.  A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.

Authors:  Michael S Gordon; Lee S Rosen; David Mendelson; Ramesh K Ramanathan; Jonathan Goldman; Lili Liu; Yan Xu; Stanton L Gerson; Stephen P Anthony; William D Figg; Shawn Spencer; Bonne J Adams; Charles P Theuer; Bryan R Leigh; Glen J Weiss
Journal:  Invest New Drugs       Date:  2012-09-29       Impact factor: 3.850

3.  Radiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic function by TGF-beta1-mediated tissue fibrosis.

Authors:  Tomer Avraham; Alan Yan; Jamie C Zampell; Sanjay V Daluvoy; Adriana Haimovitz-Friedman; Andrew P Cordeiro; Babak J Mehrara
Journal:  Am J Physiol Cell Physiol       Date:  2010-06-02       Impact factor: 4.249

4.  Methoxyamine Enhances 5-Fluorouracil-Induced Radiosensitization in Colon Cancer Cell Line HT29.

Authors:  Samideh Khoei; Roghayeh Poorabdollahi; Ahmad Mostaar; Fariborz Faeghi
Journal:  Cell J       Date:  2017-02-22       Impact factor: 2.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.